Hemogenyx Pharmaceuticals (HEMO)

Sell: 1.02p

Buy: 1.25p

Change: 0.05p | 4.59%

Last updated 16:19 13/11/24. Prices delayed by at least 15 minutes. Change is calculated based on previous close price.

Company information

Company listing information, company shareholders as well as key dates and contact details.

This share factsheet isn’t an investment recommendation. We don’t offer personal advice so if you’re unsure, please seek independent advice. Remember, the value of investments can fall as well as rise and you may get back less than you invest.

Business summary

Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.

Brands

None

Listing information

  • Share information

  • EPIC: HEMO
  • Sector: Pharmaceuticals & Biotechnology
  • ISIN: GB00BYX3WZ24
  • Market Sector: MAIN
  • Market Segment: SSQ3
  • Main Indices: n/a
  • Country of register: Great Britain
  • Currency: British Pound
  • Market Cap: £15.58m
  • NMS: 150,000
  • Shares in issue: 1,341.82m
  • Date Listed: n/a
  • Registrar: n/a
  • Exchange: London stock exchange
  • Additional listings

  • Domestic listings: BATSLON:SILFL
  • Overseas listings: n/a

Key dates

  • Dividends

  • Ex-div date (interim): n/a
  • Latest Pay Date (interim): n/a
  • View dividends
  • Meetings

  • AGM: 27/06/2024
  • EGM: n/a

Company shareholders

Last updated 31/12/2023

*Major shareholders are individuals or institutions that own more than 3% of the company’s shares and have been reported in the annual accounts.

View company shareholders breakdown

Contact details

Address: 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR

Website: n/a

Telephone: http://hemogenyx.com/

Thinking about investing?

In order to invest, you’ll first need to be a Smart Investor customer. Compare our accounts and choose the right one for you.

Compare accounts

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

Copyright © 2024 Refinitiv, an LSEG business. All rights reserved.